1 citations,
January 2023 in “International journal of medical science and clinical research studies” Treating stubborn hair loss involves both medical and emotional support options.
2 citations,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
August 2020 in “Ugeskrift for Læger” A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
4 citations,
July 2018 in “PubMed” Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
7 citations,
March 2021 in “Journal of the American Academy of Dermatology” Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
130 citations,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
144 citations,
September 2012 in “Genes & development” Aging causes skin stem cells to work less effectively.
6 citations,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
2 citations,
October 2018 in “Springer eBooks” Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.
Baricitinib is a new, effective treatment for advanced alopecia areata but is costly and has risks.
14 citations,
July 2021 in “Biomolecules” Centipeda minima extract helps hair grow by activating important growth signals and could be a promising hair loss treatment.
2 citations,
October 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” AIRE deficiency causes hair loss similar to alopecia areata in mice.
1 citations,
November 2011 in “British journal of pharmacology” Enzymes are classified into six types and are essential for many biological processes, with only a few targeted by drugs.
37 citations,
November 2017 in “Medical Sciences” Melanoma's complexity requires personalized treatments due to key genetic mutations and tumor-initiating cells.
March 2022 in “Journal of Investigative Dermatology” Discoid Lupus Erythematosus causes scalp plaques that can lead to hair loss, and antimalarial drugs are effective treatments.
78 citations,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
68 citations,
November 2015 in “The Journal of Allergy and Clinical Immunology” Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.
20 citations,
December 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.
11 citations,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
26 citations,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
August 2023 in “Indian journal of pediatrics/Indian Journal of Pediatrics” Topical treatments helped a child with Down syndrome and severe hair loss regrow most of his hair.
54 citations,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
44 citations,
September 2015 in “Annals of Oncology” Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
27 citations,
September 2017 in “Archives of Dermatological Research” Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.
9 citations,
April 2018 in “Journal of Dermatological Treatment” Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
1 citations,
October 2020 in “Journal of Cosmetic Dermatology” Using minoxidil and tofacitinib together can effectively treat severe hair loss.
February 2024 in “Scientific reports” Four genes are potential markers for hair loss condition alopecia areata, linked to a specific type of cell death.